Lung Cancer Recurrent
6
1
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating